Scalper1 News
Biotech ZS Pharma (ZSPH) popped to a new high Friday after it agreed to be bought by British drug giant AstraZeneca (AZN) for $2.7 billion. AstraZeneca will pay $90 a share in cash, a 42% premium on ZS Pharma’s Thursday closing price. AstraZeneca’s press release touted ZS Pharma’s drug ZS-9, a treatment for high potassium in the blood associated with kidney disease and heart failure. AstraZeneca said that peak annual sales of ZS-9, which is Scalper1 News
Scalper1 News